Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T18:33:25.198Z Has data issue: false hasContentIssue false
  • English
  • Français

A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection*

Published online by Cambridge University Press:  19 October 2009

A. Goodeve ,
C. W. Potter ,
A. Clark ,
R. Jennings ,
G. C. Schild  and
R. Yetts
A. Goodeve
Affiliation:
Department of Virology, The University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX
C. W. Potter
Affiliation:
Department of Virology, The University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX
A. Clark
Affiliation:
Department of Virology, The University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX
R. Jennings
Affiliation:
Department of Virology, The University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX
G. C. Schild
Affiliation:
National Institutes for Biological Standards and Control, Holly Hill, Hampstead, London NW3 5RB
R. Yetts
Affiliation:
National Institutes for Biological Standards and Control, Holly Hill, Hampstead, London NW3 5RB
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

One hundred and nineteen volunteers were divided into five groups, and each volunteer inoculated subcutaneously with an aqueous subunit B/Hong Kong/73 vaccine containing 40, 20, 10, or 5 μg of HA or saline alone in a 0·5 ml volume. The incidence of reactions was recorded 24 h after inoculation. One month following immunization the serum HI antibody to B/Hong Kong/73 virus was measured; each volunteer was inoculated intranasally with live, attenuated influenza B (RB77) virus; and the incidence of infection by the challenge virus was determined by HI antibody response.

The results showed that the incidence of reactions to all doses of vaccine were relatively low, the severity mild, and the duration short. However, the incidence of reactions was highest for those given 40 μg HA and least for those given 5 μg HA. The serum HI antibody responses to vaccine showed a dose-response relationship. For volunteers given 40 μg HA, 22 (96%) showed a fourfold rise in antibody titre and all volunteers had antibody titres of > 40 following immunization: for volunteers given 5 μg HA the g.m.t. increased from 16·6 to 86·1; and for those given 10 and 20 μg HA the response was intermediate. Following challenge, the lowest incidence of infection was seen in volunteers given the highest dose of vaccine. However, all doses of vaccine induced some protection against challenge virus infection, and the incidence of infection was directly related to the serum antibody titre at the time of challenge. The 50% protection titre of serum HI antibody was estimated as 15 to 20.

Type
Research Article
Information
Journal of Hygiene , Volume 90 , Issue 1 , February 1983 , pp. 107 - 115
Copyright
Copyright © Cambridge University Press 1983

References

REFERENCES

Bachmayer, H. (1975). Selective solubilization of haemagglutinin and neuraminidase from influenza viruses. Intervirology 5, 260–272.CrossRefGoogle ScholarPubMed
Hobson, D., Beare, A. S. & Ward-Gardner, A. (1972). Haemagglutination-inhibiting serum antibody titres as an index of response of volunteers to intranasal infection with live, attenuated strains of influenza virus. Proceedings of the Symposium on Live Influenza Vaccines, Zagreb 1971, pp. 73–84. Yugoslav Academy of Sciences and Arts.Google Scholar
Jennings, R., Clark, A., Oxford, J. S., Hockley, D. S. & Potter, C. W. (1978). Reactogenicity and immunogenicity of whole and ether-tween split influenza A vaccines in volunteers. The Journal of Infectious Diseases 138, 577–586.CrossRefGoogle ScholarPubMed
Kilbourne, E. D. (1975). The Influenza Viruses and Influenza. Academic Press: London.Google ScholarPubMed
La, Montaone J. R. (1980). Summary of a workshop on Influenza B viruses and Reye's Syndrome. The Journal of Infectious Diseases 142, 452–465.Google Scholar
Meiklejohn, G., Kempe, C. H., Tahalman, W. G. & Lennette, E. H. (1952). Evaluation of monovalent influenza vaccines. Observations during an influenza A-prime epidemic. American Journal of Hygiene 55, 12–21.Google ScholarPubMed
Nicholson, K. G., Tyrrell, D. A. J., Harrison, P., Potter, C. W., Jennings, R., Clark, A., Schild, G. C., Wood, J. M., Seagroatt, V., Higgins, A. & Anderson, S. G. (1970). Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. Journal of Biological Standardization 7, 123–136.CrossRefGoogle Scholar
Oxford, J. S., Yetts, R. & Schild, G. C. (1982). Quantitation and analysis of the specificity Influenza B vaccine in volunteers 115 of post-immunization antibodies to influenza B viruses using single radial haemolysis. Journal of Hygiene 88, 325–333.CrossRefGoogle Scholar
Potter, C. W., Jennings, R., Nicholson, K., Tyrrell, D. A. J. & Dickinson, K. G. (1977). Immunity to attenuated influenza virus WRL105 infection induced by heterologous inactivated influenza A virus vaccines. Journal of Hygiene 79, 321–332.CrossRefGoogle Scholar
Potter, C. W. & Oxford, J. S. (1970). Determinants of immunity to influenza infection in man. British Medical Bulletin 35, 69–75.CrossRefGoogle Scholar
Schild, G. C., Wood, J. M. & Newman, R. W. (1975). A single-radial-diffusion technique for the assay of influenza haemagglutinin antigen. Bulletin of the World Health Organization 52, 223–231.Google ScholarPubMed
Stuart-Harris, C. H. & Schild, G. C. (1976). Influenza: The Virus and the Disease. London: Edward Arnold.Google Scholar
W.H.O. (1953). Expert Committee on Respiratory Virus Disease. World Health Organization Technical Report, no. 64. Geneva: World Health Organization.Google Scholar
Wood, J. M., Schild, G. C., Newman, R. W. & Seagroatt, V. (1977). An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen. Application for potency determination of inactivated whole virus and subunit vaccines. Journal of Biological Standardization 5, 237–247.CrossRefGoogle ScholarPubMed